Is ANGO or FOCL more profitable?

AngioDynamics has a net margin of -11.48% compared to FocalTherics' net margin of -56.26%. AngioDynamics' return on equity of -5.73% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets AngioDynamics -11.48% -5.73% -3.77% FocalTherics -56.26% -248.00% -44.69%

Does the media refer more to ANGO or FOCL?

In the previous week, AngioDynamics and AngioDynamics both had 2 articles in the media. FocalTherics' average media sentiment score of 1.45 beat AngioDynamics' score of 1.19 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FOCL or KIDS?

In the previous week, OrthoPediatrics had 14 more articles in the media than FocalTherics. MarketBeat recorded 16 mentions for OrthoPediatrics and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat OrthoPediatrics' score of 0.40 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OrthoPediatrics 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FOCL or BWAY more profitable?

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% Brainsway 15.65% 12.74% 8.17%

Does the media favor FOCL or BWAY?

In the previous week, Brainsway had 10 more articles in the media than FocalTherics. MarketBeat recorded 12 mentions for Brainsway and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat Brainsway's score of 0.30 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DCTH or FOCL?

In the previous week, Delcath Systems had 2 more articles in the media than FocalTherics. MarketBeat recorded 4 mentions for Delcath Systems and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat Delcath Systems' score of 0.58 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, FOCL or NPCE?

NeuroPace has higher revenue and earnings than FocalTherics. NeuroPace is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $79.31M 1.94 -$29.25M -$1.03 N/A NeuroPace $106.99M 4.50 -$21.47M -$0.57 N/A

Is FOCL or NPCE more profitable?

NeuroPace has a net margin of -19.34% compared to FocalTherics' net margin of -56.26%. NeuroPace's return on equity of -105.64% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% NeuroPace -19.34% -105.64% -16.51%

Does the media favor FOCL or NPCE?

In the previous week, NeuroPace had 1 more articles in the media than FocalTherics. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat NeuroPace's score of 1.10 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

FocalTherics (FOCL) Competitors

$4.10 -0.06 (-1.44%)

As of 09/11/2026 04:00 PM Eastern

Compare

FOCL vs. ANGO, KIDS, BWAY, DCTH, and NPCE

Should you buy FocalTherics stock or one of its competitors? FocalTherics's main competitors and comparable companies include AngioDynamics (ANGO), OrthoPediatrics (KIDS), Brainsway (BWAY), Delcath Systems (DCTH), and NeuroPace (NPCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does FocalTherics compare to AngioDynamics?

AngioDynamics (NASDAQ:ANGO) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, AngioDynamics and AngioDynamics both had 2 articles in the media. FocalTherics' average media sentiment score of 1.45 beat AngioDynamics' score of 1.19 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

FocalTherics has lower revenue, but higher earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	1.97	-$36.74M	-$0.87	N/A
FocalTherics	$79.31M	1.94	-$29.25M	-$1.03	N/A

AngioDynamics has a net margin of -11.48% compared to FocalTherics' net margin of -56.26%. AngioDynamics' return on equity of -5.73% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
FocalTherics	-56.26%	-248.00%	-44.69%

AngioDynamics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

AngioDynamics presently has a consensus target price of $19.50, indicating a potential upside of 27.70%. FocalTherics has a consensus target price of $7.75, indicating a potential upside of 89.02%. Given FocalTherics' higher probable upside, analysts clearly believe FocalTherics is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

AngioDynamics beats FocalTherics on 9 of the 14 factors compared between the two stocks.

How does FocalTherics compare to OrthoPediatrics?

FocalTherics (NASDAQ:FOCL) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Comparatively, 32.5% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, OrthoPediatrics had 14 more articles in the media than FocalTherics. MarketBeat recorded 16 mentions for OrthoPediatrics and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat OrthoPediatrics' score of 0.40 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OrthoPediatrics has a net margin of -15.72% compared to FocalTherics' net margin of -56.26%. OrthoPediatrics' return on equity of -8.10% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
OrthoPediatrics	-15.72%	-8.10%	-5.54%

FocalTherics has higher earnings, but lower revenue than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$79.31M	1.94	-$29.25M	-$1.03	N/A
OrthoPediatrics	$236.35M	2.44	-$39.65M	-$1.68	N/A

FocalTherics currently has a consensus price target of $7.75, suggesting a potential upside of 89.02%. OrthoPediatrics has a consensus price target of $26.44, suggesting a potential upside of 19.88%. Given FocalTherics' higher probable upside, equities research analysts plainly believe FocalTherics is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

FocalTherics has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Summary

OrthoPediatrics beats FocalTherics on 11 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Brainsway?

FocalTherics (NASDAQ:FOCL) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Brainsway has a net margin of 15.65% compared to FocalTherics' net margin of -56.26%. Brainsway's return on equity of 12.74% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Brainsway	15.65%	12.74%	8.17%

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

FocalTherics has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Brainsway has lower revenue, but higher earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$79.31M	1.94	-$29.25M	-$1.03	N/A
Brainsway	$52.22M	10.73	$7.57M	$0.44	31.66

In the previous week, Brainsway had 10 more articles in the media than FocalTherics. MarketBeat recorded 12 mentions for Brainsway and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat Brainsway's score of 0.30 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

FocalTherics presently has a consensus target price of $7.75, suggesting a potential upside of 89.02%. Brainsway has a consensus target price of $18.20, suggesting a potential upside of 30.65%. Given FocalTherics' higher possible upside, research analysts clearly believe FocalTherics is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Brainsway beats FocalTherics on 12 of the 17 factors compared between the two stocks.

How does FocalTherics compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Delcath Systems currently has a consensus price target of $23.17, suggesting a potential upside of 45.61%. FocalTherics has a consensus price target of $7.75, suggesting a potential upside of 89.02%. Given FocalTherics' higher possible upside, analysts clearly believe FocalTherics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Delcath Systems had 2 more articles in the media than FocalTherics. MarketBeat recorded 4 mentions for Delcath Systems and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat Delcath Systems' score of 0.58 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Delcath Systems has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Delcath Systems has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$95.42M	5.79	$2.70M	$0.01	1,591.00
FocalTherics	$79.31M	1.94	-$29.25M	-$1.03	N/A

Delcath Systems has a net margin of 0.56% compared to FocalTherics' net margin of -56.26%. Delcath Systems' return on equity of 0.46% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
FocalTherics	-56.26%	-248.00%	-44.69%

Summary

Delcath Systems beats FocalTherics on 13 of the 16 factors compared between the two stocks.

How does FocalTherics compare to NeuroPace?

FocalTherics (NASDAQ:FOCL) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

NeuroPace has higher revenue and earnings than FocalTherics. NeuroPace is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$79.31M	1.94	-$29.25M	-$1.03	N/A
NeuroPace	$106.99M	4.50	-$21.47M	-$0.57	N/A

In the previous week, NeuroPace had 1 more articles in the media than FocalTherics. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.45 beat NeuroPace's score of 1.10 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

FocalTherics has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market.

FocalTherics currently has a consensus target price of $7.75, suggesting a potential upside of 89.02%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 37.36%. Given FocalTherics' higher probable upside, equities analysts plainly believe FocalTherics is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

NeuroPace has a net margin of -19.34% compared to FocalTherics' net margin of -56.26%. NeuroPace's return on equity of -105.64% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
NeuroPace	-19.34%	-105.64%	-16.51%

Summary

NeuroPace beats FocalTherics on 13 of the 16 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$156.12M	$5.38B	$7.14B	$12.72B
Dividend Yield	N/A	1.79%	2.56%	11.15%
P/E Ratio	-3.98	25.09	275.24	25.29
Price / Sales	1.94	82.90	656.02	98.94
Price / Cash	N/A	32.53	77.04	51.44
Price / Book	7.88	5.97	10.33	6.20
Net Income	-$29.25M	$150.75M	$3.50B	$358.50M
7 Day Performance	-1.20%	-2.83%	-3.32%	-2.35%
1 Month Performance	-13.68%	-3.09%	-0.41%	-2.77%
1 Year Performance	N/A	9.34%	19.21%	7.63%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	4.2715 of 5 stars	$4.10 -1.4%	$7.75 +89.0%	N/A	$156.12M	$79.31M	N/A	230	Positive News
ANGO AngioDynamics	2.9746 of 5 stars	$15.22 +0.1%	$19.50 +28.1%	+39.3%	$629.04M	$320.17M	N/A	760
KIDS OrthoPediatrics	3.9619 of 5 stars	$22.22 -0.8%	$26.44 +19.0%	+8.5%	$580.16M	$252.72M	N/A	200	Trending News Insider Trade
BWAY Brainsway	4.5839 of 5 stars	$14.16 +0.1%	$18.20 +28.5%	+77.5%	$569.37M	$52.22M	32.18	120	News Coverage Analyst Forecast
DCTH Delcath Systems	3.3688 of 5 stars	$16.08 -2.4%	$23.17 +44.1%	+42.9%	$557.98M	$85.23M	1,609.61	60	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. ANGO, KIDS, BWAY, DCTH, and NPCE

How does FocalTherics compare to AngioDynamics?

Summary

How does FocalTherics compare to OrthoPediatrics?

Summary

How does FocalTherics compare to Brainsway?

Summary

How does FocalTherics compare to Delcath Systems?

Summary

How does FocalTherics compare to NeuroPace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. ANGO, KIDS, BWAY, DCTH, and NPCE

How does FocalTherics compare to AngioDynamics?

Does the media refer more to ANGO or FOCL?

Do insiders and institutionals hold more shares of ANGO or FOCL?

Which has higher earnings and valuation, ANGO or FOCL?

Is ANGO or FOCL more profitable?

Which has more volatility & risk, ANGO or FOCL?

Do analysts prefer ANGO or FOCL?

Summary

How does FocalTherics compare to OrthoPediatrics?

Do insiders & institutionals have more ownership in FOCL or KIDS?

Does the media prefer FOCL or KIDS?

Is FOCL or KIDS more profitable?

Which has better earnings & valuation, FOCL or KIDS?

Do analysts rate FOCL or KIDS?

Which has more volatility & risk, FOCL or KIDS?

Summary

How does FocalTherics compare to Brainsway?

Is FOCL or BWAY more profitable?

Do insiders and institutionals have more ownership in FOCL or BWAY?

Which has more volatility and risk, FOCL or BWAY?

Which has higher valuation & earnings, FOCL or BWAY?

Does the media favor FOCL or BWAY?

Do analysts recommend FOCL or BWAY?

Summary

How does FocalTherics compare to Delcath Systems?

Do analysts prefer DCTH or FOCL?

Does the media prefer DCTH or FOCL?

Do institutionals & insiders have more ownership in DCTH or FOCL?

Which has more risk and volatility, DCTH or FOCL?

Which has higher earnings & valuation, DCTH or FOCL?

Is DCTH or FOCL more profitable?

Summary

How does FocalTherics compare to NeuroPace?

Which has stronger valuation and earnings, FOCL or NPCE?

Does the media favor FOCL or NPCE?

Do institutionals and insiders have more ownership in FOCL or NPCE?

Which has more volatility & risk, FOCL or NPCE?

Do analysts recommend FOCL or NPCE?

Is FOCL or NPCE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools